- Investors & Media
- Investors & Media
- Contact Us
Total Revenues for Second Quarter of 2019 were $35.3 Million, a 4% Increase Year-Over-Year Total Revenues for First Six Months of 2019 were $62.1 Million, a 21% Increase Year-Over-Year Gross…
Click here for the financial reports Click here for the investor call webcast REHOVOT, Israel – May 14, 2019 — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics…
Rehovot, Israel, May 7, 2019 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the first quarter and ended…
Kamada announced today receipt of a letter from the U.S. Food and Drug Administration (FDA or the Agency) stating that the Company has satisfactorily addressed the concerns and questions regarding its Inhaled Alpha-1-Antitrypsin (Inhaled AAT) program for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), previously communicated by the Agency.
Kamada announced today that it has been awarded the Israeli Outstanding Exporter Award for 2017 by the Foreign Trade Department of the Israeli Ministry of Economy and Industry. The Company received the award for the continued growth demonstrated in its export revenues.
Kamada today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission (the “SEC”).
Kamada announced today financial results for the three and 12-months
ended December 31, 2018.
Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test.
Top-line Results Anticipated in H2 2019
Kamada management will host an investment community conference call on Tuesday, February 12 at 8:30am Eastern Time to discuss these results and answer questions.
announced today the appointment of Michal Ayalon, Ph.D., as Vice President of Research and Development. She will oversee all of Kamada’s R&D and IP activities, and report directly to Amir London, Kamada’s Chief Executive Officer.
Dr. Ayalon will succeed Liliana Bar, Ph.D. who has served as Kamada’s VP R&D since 2012 and is retiring next month.